|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Stakeholder Insight: Psoriasis - Biologics are yet to make topical treatments obsolete
|
| Published Date:
March 2009
Published By:
Datamonitor
Page Count:
192
Order Code:
R313-46073
|
|
|
|
Introduction
Patient perception of disease severity drives treatment-seeking behavior in psoriasis. New therapeutic options targeting specific mechanisms are set to reshape severe psoriasis therapy. However, current biologics have not undermined first-line topical therapy. In addition to efficacy, reimbursement plays a crucial role in physicians' prescribing decisions.
Scope
Opinion from 180 practicing dermatologists, each treating at least 40 psoriasis patients per month
Including data from physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UK
Analysis of psoriasis population attributes, physicians' prescribing decisions, therapy outcomes and treatment satisfaction
Brand analysis of key pharmaceuticals used in psoriasis, including biologics and branded topical formulations
Highlights
The low estimated diagnosis rate of 54% reflects a lack of treatment-seeking by mild sufferers. Despite nearly 10 million diagnosed patients, the market value of psoriasis is constrained by reliance on generic and non-prescription treatments in mild disease.
Biologics' risk-benefit and cost-benefit ratios are coming under review. Humira (adalimumab) and Stelara (ustekinumab) stand to benefit from the withdrawal of Raptiva (efalizumab) from the EU and more stringent labeling in the US. The position of biologics in moderate to severe psoriasis is up for challenge by payers attempting to control costs.
Topical treatments are the foundation of therapy, used alone by at least 82% of mild patients. Phototherapy is a cost-effective treatment option in psoriasis unresponsive to topical therapy. Most physicians surveyed recommend phototherapy to up to 30% of patients, and payers may influence greater use of phototherapy.
Reasons to Purchase
Understand how patient behavior controls the size of the psoriasis market
Interpret physicians' priorities in prescribing personalized psoriasis treatment regimens
Assess the regional dynamics of therapy choice in psoriasis, dictated by product availability, regulation and reimbursement
Please note: this is delivered as a Zip file.
|
Similar Products
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Published Oct 2009 by Datamonitor
• Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
Published Oct 2009 by Datamonitor
• Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
Published Oct 2009 by Datamonitor
• Pipeline Insight: HIV - The Age of Convenience
Published Oct 2009 by Datamonitor
• Parkinson's Disease Market Forecast
Published Oct 2009 by Datamonitor
• Orphan Drug Strategies
Published Oct 2009 by Datamonitor
• Competitor Analysis: Coagulation Factors
Published Oct 2009 by La Merie S.L.
|
|
|
|
0 items
